We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

99 hedge funds and large institutions have $149M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $7.71M

70% more capital invested

Capital invested by funds: $87.5M → $149M (+$61.2M)

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

9% more funds holding

Funds holding: 91 → 99 (+8)

5.19% more ownership

Funds ownership: 29.99% → 35.18% (+5.2%)

Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
1.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
31
Reduced
23
Closed
14
Calls
$13.5M
Puts
$7.71M
Net Calls
+$5.81M
Net Calls Change
+$8M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$3.4M
2
N
Nuveen
North Carolina
+$2.98M
3
Barclays
Barclays
United Kingdom
+$2.08M
4
SG Americas Securities
SG Americas Securities
New York
+$2M
5
State Street
State Street
Massachusetts
+$1.67M

Top Sellers

1
RI
RTW Investments
New York
-$4.15M
2
Deutsche Bank
Deutsche Bank
Germany
-$1.1M
3
CAC
Cowen and Company
New York
-$720K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$363K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$361K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$25.5M +$332K +99,630 +2%
RI
2
RTW Investments
New York
$20.3M -$4.15M -1,245,032 -21%
Vanguard Group
3
Vanguard Group
Pennsylvania
$16.2M +$99.1K +29,746 +0.8%
Hudson Bay Capital Management
4
Hudson Bay Capital Management
Connecticut
$7.72M – – –
State Street
5
State Street
Massachusetts
$7.11M +$1.67M +500,289 +43%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$6.61M +$846K +253,773 +20%
Osaic Holdings
7
Osaic Holdings
Arizona
$5.85M -$17.1K -5,125 -0.4%
N
8
Nuveen
North Carolina
$4.87M +$2.98M +893,599 +395%
Millennium Management
9
Millennium Management
New York
$4.38M +$3.4M +1,021,695 New
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$3.84M -$349K -104,800 -10%
Two Sigma Investments
11
Two Sigma Investments
New York
$3.13M +$1.59M +476,475 +188%
Northern Trust
12
Northern Trust
Illinois
$3M -$62.2K -18,655 -3%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$2.84M +$1.35M +404,726 +157%
Barclays
14
Barclays
United Kingdom
$2.73M +$2.08M +625,543 +6,310%
Bank of America
15
Bank of America
North Carolina
$2.65M +$897K +269,201 +77%
SG Americas Securities
16
SG Americas Securities
New York
$2.57M +$2M +599,349 New
Primecap Management
17
Primecap Management
California
$2.15M – – –
WP
18
Woodline Partners
California
$2.13M +$1.65M +496,172 New
Wells Fargo
19
Wells Fargo
California
$1.82M +$1.4M +420,496 +10,711%
Marshall Wace
20
Marshall Wace
United Kingdom
$1.7M +$1.32M +397,088 New
Citadel Advisors
21
Citadel Advisors
Florida
$1.46M +$766K +229,943 +207%
JAMONY
22
Jacob Asset Management of New York
California
$1.46M – – –
Goldman Sachs
23
Goldman Sachs
New York
$1.23M +$607K +182,152 +174%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$1.1M +$56.4K +16,929 +7%
Group One Trading
25
Group One Trading
Illinois
$1.08M +$598K +179,394 +246%
1
2 3 4 5

ABUS Hedge Fund Activity: Q3 2021 in Review

99 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2021, worth a combined $149M — up 70% from $87.5M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ABUS positions and 14 closed out — a net gain of 9 holders — while 31 added to existing stakes and 23 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $3.4M. The largest seller was RTW Investments, cutting an estimated $4.15M.

  • 99 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2021, up from 91 in Q2 2021.
  • Funds reported $149M of Arbutus Biopharma stock for Q3 2021, up 70% quarter-over-quarter.
  • 23 funds opened new Arbutus Biopharma positions in Q3 2021 and 14 closed out, a net change of +9 holders.
  • The largest Arbutus Biopharma buyer in Q3 2021 was Millennium Management, an estimated $3.4M added.
  • The largest Arbutus Biopharma seller in Q3 2021 was RTW Investments, an estimated $4.15M sold.

Based on aggregated 13F filings for Q3 2021.